Live cattle futures posted gains of 37 to 67 cents at the close on Thursday. Open interest was up 2,250 contracts, as October (-2,201) was the lone exception ahead of Monday’s first notice day. October options expire today. Cash trade saw some light $348-350 dressed action in the North so...
Soybeans are kicking off Friday trade with losses of 6 to 7 cents. Futures bounced off the intraday lows on Thursday, with contracts closing 7 to 9 cents lower in the nearbys and down 1 3/4 to 6 ½ cents in deferreds. Open interest suggested a rotation of ownership, up...
Lean hog futures posted mixed trade, with front months down 22 to 50 cents and deferreds steady to 97 cents higher. Open interest was up 4,655 contracts, suggesting new modest selling. USDA’s national base hog price was reported at $76.93 on Thursday, down 79 cents from the day prior. The...
Corn futures were fighting to stay above $5 for much of the session despite hitting a low of $4.95 in the December contract. Bulls battled back to close with contracts steady to 1 ½ cents higher. The CmdtyView national average Cash Corn price was up 3 1/4 cents at $4.61...
The average one-year price target for Biodesix (NASDAQGM:BDSX) has been revised to $37.54 / share. This is an increase of 12.20% from the prior estimate of $33.46 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute
The average one-year price target for Nordic American Tankers (NYSE:NAT) (DB:B3O) has been revised to $7.11 / share. This is an increase of 12.97% from the prior estimate of $6.29 dated September 11, 2026. These figures represent an aggregate of analyst targets compiled by Fintel
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.19% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. December E-mini S&P futures (ESZ26 ) rose +0.20%, and December E-mini...
The average one-year price target for Fulcrum Therapeutics (NASDAQGM:FULC) has been revised to $7.75 / share. This is an increase of 11.22% from the prior estimate of $6.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not c
The average one-year price target for PLAYSTUDIOS (NASDAQCM:MYPS) (DB:7E3) has been revised to $5.10 / share. This is an increase of 900.00% from the prior estimate of $0.51 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not
The average one-year price target for GRAIL (NASDAQGS:GRAL) (BMV:GRAL) has been revised to $99.35 / share. This is an increase of 32.52% from the prior estimate of $74.97 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not con
Fintel reports that on October 2, 2026, Keybanc initiated coverage of SailPoint (NASDAQGS:SAIL) (DB:F0V) with a Sector Weight recommendation.Prior to this action, the stock closed at $20.58 on October 1, 2026. This latest close of $20.58 represents a price change of -6.96% over o
The S&P 500 Index ($SPX ) (SPY ) closed up by +0.19% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. December E-mini S&P futures (ESZ26 ) rose +0.20%, and December E-mini...
The average one-year price target for HeartBeam (NASDAQCM:BEAT) has been revised to $3.57 / share. This is an increase of 10.53% from the prior estimate of $3.23 dated September 11, 2026. These figures represent aggregate analyst targets compiled as of September 29, 2026, and do
Key PointsThe S&P 500 index is trading at the second-highest valuation in its history, behind only the peak of the dot-com internet bubble in 2000, leaving it vulnerable to a correction.
On October 2, 2026, Piper Sandler upgraded their outlook for Alerus Financial (NASDAQCM:ALRS) (DB:5QD) from Neutral to Overweight. This rating action follows a prior action by the same firm on July 31, 2026, when Piper Sandler maintained its Neutral rating on the stock.Alerus Fin
The average one-year price target for AEON Biopharma (NYSEAM:AEON) has been revised to $1.81 / share, up 16.39% from the prior estimate of $1.56 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation o